Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 13;9(9):2044-2047.
doi: 10.1182/bloodadvances.2024015581.

Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study

Beatrice Casadei  1 , Lisa Argnani  2 , Alessandro Broccoli  1   2 , Martina Cantelli  2 , Gabriele Gugliotta  1 , Marianna Gentilini  2 , Matteo Carella  2 , Vittorio Stefoni  1   2 , Cinzia Pellegrini  1 , Nicole Fabbri  2 , Giulia Gabrielli  2 , Camilla Mazzoni  2 , Pierluca Maglio  2 , Gianmarco Bagnato  2 , Pier Luigi Zinzani  1   2
Affiliations

Long-term efficacy of immune checkpoint inhibitors for relapsed primary mediastinal B-cell lymphoma: a real-world study

Beatrice Casadei et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
PFS and OS. Whole study population (A-B) and stratified by ICI type (C-D). PEMBRO, pembrolizumab.
See this image and copyright information in PMC

References

    1. National Cancer Institute Hematopoietic and lymphoid neoplasm database. https://seer.cancer.gov/seertools/hemelymph/
    1. Liu P-P, Wang K-F, Xia Y, et al. Racial patterns of patients with primary mediastinal large B-cell lymphoma: SEER analysis. Medicine (Baltim) 2016;95(27) - PMC - PubMed
    1. Zinzani PL, Stefoni V, Finolezzi E, et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma. 2009;9(5):381–385. - PubMed
    1. Dunleavy K, Pittaluga S, Maeda LS, et al. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med. 2013;368(15):1408–1416. - PMC - PubMed
    1. Kuruvilla J, Pintilie M, Tsang R, Nagy T, Keating A, Crump M. Salvage chemotherapy and autologous stem cell transplantation are inferior for relapsed or refractory primary mediastinal large B-cell lymphoma compared with diffuse large B-cell lymphoma. Leuk Lymphoma. 2008;49(7):1329–1336. - PubMed